Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens

References

• Adler-Moore JP. (1994). AmBisome targeting to fungal infections. Bone Marrow Transplant 14:S3–7
   PubMed Web of Science ®Google Scholar
• Adler-Moore JP, Chiang S-M, Satorius A, et al. (1991). Treatment of murine candidiasis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J Antimicrob Chemother 28:63–71
   PubMed Web of Science ®Google Scholar
• Adler-Moore JP, Gangneux JP, Pappas PG. (2016). Comparison between liposomal formulations of amphotericin B. Med Mycol 54:223–31
   PubMed Web of Science ®Google Scholar
• Adler-Moore JP, Olson JA, Proffitt RT. (2004). Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J Antimicrob Chemother 54:1096–102
   PubMed Web of Science ®Google Scholar
• Adler-Moore J, Proffitt RT. (2002). AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 49:21–30
   PubMed Web of Science ®Google Scholar
• Adler-Moore JP, Proffitt RT. (2005). Case study: AmBisome – a developmental case study of a liposomal formulation of the antifungal agent amphotericin B. In: DJ Burgess, ed. Injectable dispersed systems: formulation, processing, and performance. New York: Marcel Dekker Inc. 481–525
   Google Scholar
• Adler-Moore JP, Proffitt RT. (2008). Amphotericin B lipid preparations: what are the differences?. Clin Microbiol Infect 14:25–36
   PubMed Web of Science ®Google Scholar
• Albert MM, Stahl-Carroll L, Luther MF, Graybill JR. (1995). Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis. J Mycol Med 5:1–6
   Web of Science ®Google Scholar
• Allen SD, Sorensen KN, Nejdl MJ, et al. (1994). Prophylactic efficacy of aerosolized liposomal (AmBisome) and non liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 34:1001–13
   PubMed Web of Science ®Google Scholar
• Bekersky I, Boswell GW, Hiles R, et al. (1999). Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm Res 16:1694–701
   PubMed Web of Science ®Google Scholar
• Bekersky I, Boswell GW, Hiles R, et al. (2000). Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats. Pharm Res 17:1494–502
   PubMed Web of Science ®Google Scholar
• BitMansour A, Brown JM. (2002). Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation. J Infect Dis 186:134–7
   PubMed Web of Science ®Google Scholar
• Boswell GW, Bekersky I, Buell D, et al. (1998a). Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob Agents Chemother 42:263–8
   PubMed Web of Science ®Google Scholar
• Boswell GW, Buell D, Bekersky I. (1998b). AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 38:583–92
   PubMed Web of Science ®Google Scholar
• Cannon JP, Fiscella R, Pattharachayakul S, et al. (2003). Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci 44:2112–7
   PubMed Web of Science ®Google Scholar
• Chang T, Olson JA, Proffitt RT, Adler-Moore JP. (2010). Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B. Med Mycol 48:430–5
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. (1993a). Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J Antimicrob Chemother 32:465–72
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. (1993b). Comparison of a liposomal amphotericin B formulation (AmBisome) and deoxycholate amphotericin B (Fungizone) for the treatment of murine paracoccidioidomycosis. J Med Vet Mycol 31:387–94
   Google Scholar
• Clemons KV, Stevens DA. (1998). Comparison of Fungizone, Amphotec, AmBisome and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 42:899–902
   PubMed Web of Science ®Google Scholar
• Clemons KV, Sobel RA, Williams PL, et al. (2002). Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 46:2420–6
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Mohty M, Faucher C, et al. (2008). Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: Prophysome Study. Int J Antimicrob Agents 31:135–41
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. (2012). ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18:19–37
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, et al. (2007). Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44:1289–97
   PubMed Web of Science ®Google Scholar
• Ferreira GF, de Matos Baltazar L, Santos JRA, et al. (2013). The role of oxidative and nitrosative bursts caused by azoles and amphotericin B against the fungal pathogen Crytpococcus gattii. J Antimicrob Chemother 68:1801–11
   PubMed Web of Science ®Google Scholar
• Fielding RM, Smith PC, Wang LH, Porter J, Guo LS. (1991). Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 35:1208–13
   PubMed Web of Science ®Google Scholar
• Francis P, Lee JW, Hoffman A, et al. (1994). Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 169:356–68
   PubMed Web of Science ®Google Scholar
• Fujii G, Chang JE, Coley T, Steere B. (1997). The formation of amphotericin B ion channels in lipid bilayers. Biochemistry 36:4959–68
   PubMed Web of Science ®Google Scholar
• Gangneux JP, Sulahian A, Garin YJ, et al. (1996). Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob Agents Chemother 40:1214–8
   PubMed Web of Science ®Google Scholar
• Garcia A, Adler-Moore JP, Proffitt RT. (2000). Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis. Antimicrob Agents Chemother 44:2327–32
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Wasan EK, Lin M, et al. (2009). Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother 64:101–8
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Wasan EK, Sivak O, et al. (2010). Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. J Antimicrob Chemother 65:535–7
   PubMed Web of Science ®Google Scholar
• Gilbert BE, Proffitt R. (1996). Aerosolized AmBisome treatment of pulmonary Cryptococcus neoformans infection in mice. J Aerosol Med 9:263–76
   Google Scholar
• Gondal JA, Swartz RP, Rahman A. (1989). Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother 33:1544–8
   PubMed Web of Science ®Google Scholar
• Graybill JR, Bocanegra R. (1995). Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrob Agents Chemother 39:1885–7
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. (1976). The carrier potential of liposomes in biology and medicine. N Engl J Med 295:704–10
   PubMed Web of Science ®Google Scholar
• Groll AH, Giri N, Petraitis V, et al. (2000a). Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 182:274–82
   PubMed Web of Science ®Google Scholar
• Groll AH, Mickiene D, Piscitelli SC, Walsh TJ. (2000b). Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits. Antimicrob Agents Chemother 44:408–10
   PubMed Web of Science ®Google Scholar
• Guo LSS, Fielding RM, Lasic DD, et al. (1991). Novel antifungal drug delivery: stable amphotericin B–cholesteryl sulfate discs. Int J Pharma 75:45–54
   Web of Science ®Google Scholar
• Hamill RJ, Sobel JD, El-Sadr W, et al. (2010). Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-Associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis 51:225–32
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebremariam T, Husseiny MI, et al. (2008). Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 52:1573–6
   PubMed Web of Science ®Google Scholar
• Janoff AS, Boni LT, Popescu MC, et al. (1988). Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A 85:6122–6
   PubMed Web of Science ®Google Scholar
• Jensen GM, Skenes CR, Bunch TH, et al. (1999). Determination of the relative toxicity of amphotericin B formulations: a red blood cell potassium release assay. Drug Deliv 6:81–8
   Web of Science ®Google Scholar
• Jensen GM, Bunch TH, Hu N, Eley CGS. (2006). Process development and quality control of injectable liposome therapeutics. In: Gregoriadis G, ed. Liposome technology. 3rd ed. Vol. I. Liposome preparation and related techniques. New York: Informa Healthcare, 297–310
   Google Scholar
• Johnson PC, Wheat LJ, Cloud GA, et al. (2002). Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 137:105–9
   PubMed Web of Science ®Google Scholar
• Kaji Y, Yamamoto E, Hiraoka T, Oshika T. (2009). Toxicities and pharmacokinetics of subconjunctival injection of liposomal amphotericin B. Graefes Arch Clin Exp Ophthalmol 247:549–53
   PubMed Web of Science ®Google Scholar
• Kuhn DM, George T, Chandra J, et al. (2002). Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother 46:1773–80
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C, Mayr A, Perkhofer S, et al. (2008). Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 52:3637–41
   PubMed Web of Science ®Google Scholar
• Lee JW, Amantea MA, Francis PA, et al. (1994). Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 38:713–8
   PubMed Web of Science ®Google Scholar
• Lestner JM, Howard SJ, Goodwin J, et al. (2010). Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 54:3432–41
   PubMed Web of Science ®Google Scholar
• Lewis RE, Liao G, Hou J, et al. (2007). Comparative lung accumulation and fungal clearance in a murine model of acute invasive pulmonary analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of aspergillosis. Antimicrob Agents Chemother 51:1253–8
   PubMed Web of Science ®Google Scholar
• Lewis RE, Albert ND, Kontoyiannis DP. (2008). Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 52:4178–80
   PubMed Web of Science ®Google Scholar
• Lewis RE, Albert ND, Liao G, et al. (2010). Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 54:1298–304
   PubMed Web of Science ®Google Scholar
• Olsen SJ, Swerdel MR, Blue B, et al. (1991). Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol 43:831–5
   PubMed Web of Science ®Google Scholar
• Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT. (2005). Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal Amphotericin B with caspofungin or micafungin. Antimicrob Agents and Chemother 49:4895–902
   PubMed Web of Science ®Google Scholar
• Olson JA, Adler-Moore JP, Schwartz J, et al. (2006). Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 50:2122–31
   PubMed Web of Science ®Google Scholar
• Olson JA, Adler-Moore JP, Jensen GM, et al. (2008). Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob Agents Chemother 52:259–68
   PubMed Web of Science ®Google Scholar
• Olson JA, George A, Constable D, et al. (2010). Liposomal Amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrob Agents Chemother 54:3884–94
   PubMed Web of Science ®Google Scholar
• Olson JA, Schwartz JA, Hahka D, et al. (2015). Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice. Med Mycol 53:107–18
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D, Jacobson K, Nir S, Isac T. (1973). Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim Biophys Acta 311:330–48
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. (2016). Clinical practice guideline for the management of candidiasis:2016 update by the infectious diseases society of America. Clin Infect Dis 62:e1–50
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, 3rd, Denning DW, et al. (2016). Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis 63:e1–60
   PubMed Web of Science ®Google Scholar
• Prentice HG, Hann IM, Hebrecht R, et al. (1997). A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98:711–8
   PubMed Web of Science ®Google Scholar
• Proffitt RT, Satorius A, Chiang S-M, et al. (1991). Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 28:49–61
   PubMed Web of Science ®Google Scholar
• Ramaswamy M, Peteherych KD, Kennedy AL, Wasan KM. (2001). Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob Agents Chemother 45:1184–91
   PubMed Web of Science ®Google Scholar
• Readio JD, Bittman R. (1982). Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols. Biochim Biophys Acta 685:219–24
   PubMed Web of Science ®Google Scholar
• Schinabeck MK, Long LA, Hossain MA, et al. (2004). Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob Agents Chemother 48:1727–32
   PubMed Web of Science ®Google Scholar
• Smith PJ, Olson JA, Constable D, et al. (2007). Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J Antimicrob Chemother 59:941–51
   PubMed Web of Science ®Google Scholar
• Spellberg B, Schwartz J, Fu Y, et al. (2006). Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother 58:973–9
   PubMed Web of Science ®Google Scholar
• Takemoto K, Yamamoto Y, Ueda Y, et al. (2006). Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. J Antimicrob Chemother 57:724–31
   PubMed Web of Science ®Google Scholar
• Toulet D, Debarre C, Imbert C. (2012). Could liposomal amphotericin B (L-AMB) lock solutions be useful to inhibit Candida spp. biofilms on silicone biomaterials?. J Antimicrob Chemother 67:430–2
   PubMed Web of Science ®Google Scholar
• van Etten EWM, van den Heuvel-de Groot C, Bakker-Woudenberg IA. (1993). Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J Antimicrob Chemother 32:723–39
   PubMed Web of Science ®Google Scholar
• van Etten EW, Otte-Lambillion M, van Vianen W, et al. (1995). Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother 35:509–19
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. (1999). Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340:764–71
   PubMed Web of Science ®Google Scholar
• Wasan KM, Sivak O, Rosland M, et al. (2006). Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet(®) and AmBisome(®) in combination with caspofungin to rats infected with Aspergillus fumigatus. J Pharm Sci 96:1737–47
   Web of Science ®Google Scholar
• Wasan KM, Wasan EK, Gershkovich P, et al. (2009). Highly effective oral Amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis 200:357–60
   PubMed Web of Science ®Google Scholar
• Wingard JR, White MH, Anaissie E, et al. (2000). A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 31:1155–63
   PubMed Web of Science ®Google Scholar